ArticleMolecular & cellular proteomics : MCP2014
Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry.
Article in Molecular & cellular proteomics : MCP, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.PloS one · 2021Trial
- Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2018Trial
- Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Trial
- Identification of Pre-Diagnostic Protein Biomarkers for Liver Cirrhosis Based on Prospective Analysis of a Large-Scale Plasma Proteomics in the UK Biobank.Proteomics. Clinical applications · 2026Article
- Exploring new frontiers in type 1 diabetes through advanced mass-spectrometry-based molecular measurements.Trends in molecular medicine · 2024Review
- Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-β1 (TGF-β1) availability and inhibits hepatocarcinogenesis.Cancer communications (London, England) · 2024Article
- Serum dithiothreitol-oxidizing capacity (DOC) is a promising biomarker for excluding significant liver fibrosis: a proof-of-concept study.BMC medicine · 2024Article
- Longitudinal analysis of host protein serum signatures of treatment and recovery in pulmonary tuberculosis.PloS one · 2024Article
- Towards IMInternational journal of mass spectrometry · 2024Article
- Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis.The American journal of pathology · 2022Article
- Noninvasive proteomic biomarkers for alcohol-related liver disease.Nature medicine · 2022Article
- A Preprocessing Tool for Enhanced Ion Mobility-Mass Spectrometry-Based Omics Workflows.Journal of proteome research · 2022Article
- Glycoproteomic Analysis of Human Urinary Exosomes.Analytical chemistry · 2020Article
- Proteomic assessment of serum biomarkers of longevity in older men.Aging cell · 2020Article
- Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.Journal of proteomics · 2020Article
- Fundamentals of Ion Mobility-Mass Spectrometry for the Analysis of Biomolecules.Methods in molecular biology (Clifton, N.J.) · 2020Review
- Ion Mobility Spectrometry and the Omics: Distinguishing Isomers, Molecular Classes and Contaminant Ions in Complex Samples.Trends in analytical chemistry : TRAC · 2019Article
- Improved Sensitivity and Separations for Phosphopeptides using Online Liquid Chromotography Coupled with Structures for Lossless Ion Manipulations Ion Mobility-Mass Spectrometry.Analytical chemistry · 2018Article
- Evaluating lipid mediator structural complexity using ion mobility spectrometry combined with mass spectrometry.Bioanalysis · 2018Article
- Coupling Front-End Separations, Ion Mobility Spectrometry, and Mass Spectrometry For Enhanced Multidimensional Biological and Environmental Analyses.Annual review of analytical chemistry (Palo Alto, Calif.) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Rapid diagnosis of disease states using less invasive, safer, and more clinically acceptable approaches than presently employed is a crucial direction for the field of medicine. While MS-based proteomics approaches have attempted to meet these objectives, challenges such as the enormous dynamic range of protein concentrations in clinically relevant biofluid samples coupled with the need to address human biodiversity have slowed their employment. Herein, we report on the use of a new instrumental platform that addresses these challenges by coupling technical advances in rapid gas phase multiplexed ion mobility spectrometry separations with liquid chromatography and MS to dramatically increase measurement sensitivity and throughput, further enabling future high throughput MS-based clinical applications. An initial application of the liquid chromatography--ion mobility spectrometry-MS platform analyzing blood serum samples from 60 postliver transplant patients with recurrent fibrosis progression and 60 nontransplant patients illustrates its potential utility for disease characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.